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Wehavepreviouslyreportedthat,inhumangranulosacells,thiazolidinedionesrosiglitazoneandpioglitazoneinhibitestrogensyn-
thesis by interfering with androgen binding to aromatase, without an eﬀect on aromatase mRNA or protein expression. In the
currentpaper,weexploretheeﬀectsofrosiglitazoneandpioglitazoneonthearomataseenzymekineticpropertiesinhumangranu-
losacells.Thecellswereincubatedwithvariousconcentrationsoftestosteroneorandrostenedione,withorwithoutrosiglitazoneor
pioglitazone.Estradiolandestroneconcentrationsintheconditionedtissueculturemediumweremeasuredbyradioimmunoassay
or immunosorbent assay. When testosterone was used as substrate, rosiglitazone or pioglitazone inhibited the Vmax by 35%
(P<0.001) and 24% (P<0.001), respectively. When androstenedione was used as substrate, both rosiglitazone or pioglitazone
inhibited Vmax by 13% (P<0.007). We conclude that rosiglitazone or pioglitazone has no eﬀect on Km but inhibits Vmax of aroma-
tase in human granulosa cells, therefore, acting as noncompetitive inhibitors.
1.Introduction
Thiazolidinediones (TZDs: troglitazone, rosiglitazone, and
pioglitazone)areperoxisomeproliferator-activatedreceptor-
γ (PPAR-γ) agonists, which have been used in the treatment
of type 2 diabetes as insulin sensitizers. TZDs have also been
used as therapeutic agents for women with polycystic ovary
syndrome (PCOS) since they reduce androgen levels and im-
prove ovulatory rates [1–4]. Although the eﬀects of TZDs
in the female reproductive system have been attributed to
their systemic insulin-sensitizing properties and consequent
reduction in hyperinsulinemia [5], TZDs also directly aﬀect
androgen and estrogen production in human ovarian cells
[6].
Aromatase is a cytochrome P450 superfamily enzyme
that converts androgens to estrogens. The literature on the
TZD eﬀects on aromatase activity in the ovary is controver-
sial [7–9]. Our previous studies demonstrated that rosigli-
tazone or pioglitazone directly inhibit estrogen synthesis in
the mixed human ovarian cell culture containing stromal,
thecal, and granulosa cells and in puriﬁed human granulosa
cells obtained from in vitro fertilization [6, 10]. We recently
reported that rosiglitazone or pioglitazone also interfere with
androgen binding to aromatase enzyme, suggesting that
TZDs may aﬀect the aromatase enzyme kinetic properties
[10].
The goal of this study, therefore, was to examine the
eﬀects of TZDs on the enzyme kinetic properties of aro-
matase.
2.MaterialsandMethods
The institutional review boards at the Beth Israel Medical
Center and the Weill Medical College of Cornel University
approved all studies described in this paper.
2.1. Human Granulosa Cells and Cell Culture. Human gran-
ulosa cells obtained during in vitro fertilization (IVF) were2 PPAR Research
pooled from several patients at a time to ensure adequate cell
numberfortheexperiments.Diagnosesincludedmalefactor,
tubal factor, and uterine factor infertility, endometriosis, or
anovulation [10]. Human granulosa cells obtained during in
vitrofertilization were puriﬁed on the Percoll gradients (50%
Percoll/Hank’s balanced salt solution) as previously descri-
bed [10]. Puriﬁed human granulosa cells were counted using
hemocytometer, and 1mL of 0.5 × 105 cells/mL suspension
w a sp l a c e di n2 4w e l lt i s s u ec u l t u r ep l a t e s[ 10]. The cells
were cultured for 48 hours at 37◦C, 5% CO2, 90% humidity
in M199 medium supplemented with 10% FBS, 10μg/mL
gentamicin, and 250ng/mL amphotericin B. After 48 hours
of incubation, the medium supplemented with 10% FBS was
replaced by a medium with 2% FBS, in which the cells were
incubated for additional 24h before the kinetic experiments
were performed.
2.2. Enzyme Kinetic Studies. For the aromatase enzyme
kinetic studies, cells were incubated with various concentra-
tions of testosterone (0.025, 0.05, 0.1, 0.133, 0.25, or 1.0μM)
or androstenedione (0.025, 0.05, 0.1, 0.133, 0.25, 0.5, or
1.0μM) for 150min, in the presence or absence of 25μM
rosiglitazone or pioglitazone. The conditioned tissue cul-
ture medium was collected for determination of estrone
and estradiol concentrations. Several time points (150min,
240min, 360min, and 720min) were included in the
kinetic experiments. The velocity of aromatase activity
(μMestradiol/mg/min)was0.14,0.25,0.22,and0.28,respec-
tively, for the 150, 240, 360, and 720min of the reaction time
points. Because 150min incubation time produced a linear
reaction, this time point was chosen for the kinetic studies.
The concentrations of the substrates were extended to those
below and above the Km.
2.3. Protein Measurement. Protein concentrations were det-
ermined by BCA (Bicinchoninic Acid Assay) [11].
2.4. Radioimmunoassay and Immunosorbent Assay. Estrone
concentrations in the tissue culture medium were measured
using enzyme-linked immunosorbent assay (ELISA). The
cross-reactivity with estrone is 100%, with estradiol 2.2%,
and with other related compounds 0.14%. Estradiol concen-
tration was measured using radioimmunoassay (RIA). The
cross-reactivity with 17β-estradiol is 100% and with other
related compounds less than 1%.
2.5. Materials. M199 medium, heat-inactivated fetal bovine
serum (FBS), gentamicin, and amphotericin were obtained
from Invitrogen Corp., Carlsbad, CA, USA; testosterone
and androstenedione were from Sigma-Aldrich Corp., St.
Louis, Mo; rosiglitazone was from Cayman Chemical, Ann
Arbor, Mich; pioglitazone was from Takeda Pharmaceuticals
America, Inc. Lincolnshire, IL; Lowry protein assay kits were
from Thermo Scientiﬁc, Rockford, IL, USA; estrone enzyme-
linked immuno-sorbent assay (ELISA) kits were from Alpco
Diagnostics, Salem, NH; estradiol radioimmunoassay (RIA)
kits were from the Diagnostic Systems Laboratories, Webster,
TX, USA.
2.6. Statistical Analysis. All experiments were carried out
in triplicates or quadruplicates and repeated 6 to 7 times.
Two-way analysis of variance (ANOVA) was used to com-
pare mean values according to substrate concentrations
(testosterone or androstenedione) in the presence or absence
of rosiglitazone or pioglitazone. The statistical interactions
between the sets of data obtained with or without rosiglita-
zone or pioglitazone were examined. Pairwise Bonferroni’s
adjusted contrasts were used to determine statistical signiﬁ-
cance.
3. Results
3.1. Testosterone as Substrate. When testosterone was used as
substrate, aromatase Vmax was reduced by 35% with rosigli-
tazone (P<0.001) (Figures 1(a) and 1(b)) and by 24% with
pioglitazone (P<0.001) (Figures 1(a) and 1(c)). The Km was
not aﬀected (Figure 1(d)).
3.2. Androstenedione as Substrate. When androstenedione
was used as substrate, rosiglitazone inhibited Vmax by 13%
(P<0.007) (Figures 2(a) and 2(b)). Pioglitazone also inhi-
bited Vmax by 13% (P<0.004) (Figures 2(a) and 2(c)).
Neither rosiglitazone nor pioglitazone had signiﬁcant eﬀect
on Km of aromatase (Figure 2(d)).
4. Discussion
Aromatase is a cytochrome P450 superfamily enzyme that
converts androgens to estrogens and is highly expressed in
granulosa cells. It is a key enzyme for the development of
sexual characteristics, and its function is important in the
pathogenesis of various diseases, including breast cancer
[12–14].
Conﬂicting reports have been published regarding the
eﬀects of TZDs on the expression and activity of aromatase
in the ovary [8, 9, 15]. For example, Gasic et al. reported
absence of troglitazone eﬀects on the aromatase in porcine
granulosa cells [15], while other studies reported that trogli-
tazone/LG100268 induced suppression of enzymatic expres-
sion and activity of aromatase in human granulosa cells and
in granulosa cell carcinoma cell lines [8, 9]. In our previous
studies, rosiglitazone or pioglitazone directly inhibited estro-
gensynthesisinhumanmixedovariancellculturecontaining
stromal, thecal, and granulosa cells [6]. Recently we reported
that the mechanism of rosiglitazone or pioglitazone eﬀect on
estrogen synthesis in cultured human granulosa cells does
not involve any eﬀects on either aromatase mRNA or protein
expression [10]. In contrast, another thiazolidinedione, tro-
glitazone, inhibited aromatase mRNA expression in our
studies, which is consistent with the literature [8, 9]. We also
showedthatrosiglitazoneorpioglitazoneinhibitedandrogen
binding to aromatase [10].
In this study, we examined the eﬀects of rosiglitazone
or pioglitazone on aromatase enzyme kinetic properties.
Rosiglitazone or pioglitazone inhibited Vmax of aromatase
without aﬀecting the Km, suggesting that rosiglitazone or
pioglitazone inhibit aromatase enzyme in a noncompetitive
manner (rosiglitazone or pioglitazone did not compete withPPAR Research 3
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Figure 1: Eﬀects of TZDs on aromatase enzyme kinetics when testosterone was used as substrate. (a) The Lineweaver-Burk plot (reciprocal
velocitiesofaromataseactivityagainstreciprocaltestosteroneconcentration)intheabsenceofrosiglitazoneorpioglitazone.(b)TheLinewe-
aver-Burkplotinthepresenceofrosiglitazone.(c)TheLineweaver-Burkplotinthepresenceofpioglitazone.(d)ComparisonoftheLinewea-
ver-Burk plots in the presence or absence of rosiglitazone or pioglitazone. V = velocity; S = substrate.
substrate—testosterone or androstenedione—binding to
aromatase). Our previous studies examined 125[I]-testoster-
one or 125[I]-androstenedione binding to immuno-puriﬁed
aromatase bound to protein A immobilized on agarose [10].
Iodination of the substrates and procedure used for immu-
nopuriﬁcation of aromatase may have altered the substrate
and enzyme structure in these studies. The current studies,
which involved assessing initial activity rate of aromatase in4 PPAR Research
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Figure 2: Eﬀects of TZDs on aromatase enzyme kinetics when androstenedione was used as substrate. (a) The Lineweaver-Burk plot (recip-
rocal velocities of aromatase activity against reciprocal androstenedione concentration) in the absence of rosiglitazone or pioglitazone.
(b)TheLineweaver-Burkplotinthepresenceofrosiglitazone.(c)TheLineweaver-Burkplotinthepresenceofpioglitazone.(d)Comparison
of the Lineweaver-Burk plots in the presence or absence of rosiglitazone or pioglitazone. V = velocity; S = substrate.
the presence of various concentrations of substrates, allowed
us to obtain more accurate Michaelis-Menten constants Km
and Vmax.
The competitive aromatase inhibitors (anastrozole and
letrozole)usedinclinicalpracticetotreatortopreventbreast
cancer inhibit aromatase activity by 90–100%. Rosiglitazone
andpioglitazone,incontrast,inhibitaromataseactivityby30
to50%[10].Thecurrentstudiesshowa13–35%reductionin
aromatase activity because the substrate concentrations were
between0.025and1μM,whichareeitherbeloworjustabovePPAR Research 5
the Km. In the previous studies, the substrate concentrations
were above the Km (3μM), and the incubation time was 18
hours.
This diﬀerence in potency may make thiazolidinediones
an attractive alternative to competitive aromatase inhibitors
because of presumably lower likelihood of aromatase-related
side eﬀects with TZDs (such as hot ﬂushes and reduced bone
density). In healthy postmenopausal women, annual bone
loss associated with traditional aromatase inhibitors is
higherthanthatobservedwithTZDs(2.2–2.6%versus0.5%,
resp.). Inhibition of estrogen synthesis by TZDs may make
them useful in the therapy of estrogen-dependent diseases
including breast cancer, gynecomastia, uterine ﬁbroids, and
endometrial cancer [12, 13]. Inhibition of aromatase activity
by TZDs may also help explain their negative eﬀect on bone
density in older or postmenopausal women [16, 17].
In conclusion, rosiglitazone or pioglitazone inhibits the
aromatase enzyme activity by reducing its Vmax without ef-
fect on Km, acting as noncompetitive inhibitors of the aro-
matase enzyme.
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